Dr. Laurent Yvan-Charvet obtained his Ph.D. in Endocrinology in 2005 from the University of Paris XI, France. He was the recipient of the Roger Davis Award in 2010, finalist of the I.H. Page Young Investigator Award in 2011 and recipient of the EAS young Investigator award in 2013.
His research work at Columbia University has been mainly focused on two ATP-binding cassette transporters ABCA1 and ABCG1 that mediated the cholesterol efflux potential of HDL-cholesterol (good cholesterol). These transporters are central to the metabolic complications of the immune and hematopoietic systems not only in cancer but also in cardiometabolic diseases such as atherosclerosis. Therapies aimed at raising HDL-C are currently under Phase III clinical trials.
After a contribution to the development of new therapeutics for cardiovascular diseases at Pfizer, his current research interest as a group leader lies in immune and hematopoietic cell metabolism in diseases.
Our research program primarily focuses on the ‘Metabolism of the immune and hematopoietic systems in cancer and cardiometabolic diseases with the aim to gain insight in immune metabolic complications observed in these diseases. We are currently focusing on the identification of novel metabolic pathways that could act independently or in synergy on the metabolism of immune and hematopoietic systems in myeloproliferative disease, lung cancer and cardiometabolic diseases.
The team is dedicated to achieve a deeper understanding of the metabolism of the immune and hematopoietic system in cancer and cardiometabolic diseases with the hope of identifying new candidate targets for therapeutic interventions or new predictors of disease outcomes.
Axe 1 : Metabolic abnormalities of the immune and hematopoietic systems associated to cancer cachexia. I. Role of metabolic pathways in cachexia associated to myeloproliferative disease and lung cancer. II. Identification of novel mutations in the cholesterol efflux transporter ABCA1 in myeloproliferative disorder.
These projects are supported by an European Marie Curie Career Integration Grant (CIG630926) and a national ATIP-AVENIR starting package.
Axe 2 : Metabolic abnormalities of the immune and hematopoietic systems in cardiometabolic diseases. II. Role of glycolytic pathways on cardiometabolic diseases II. Role of cholesterol efflux pathways on cardiometabolic diseases.
These projects are supported by a grant from the Agence Nationale de la Recherche (ANR) and the Fondation de France (FDF).
Lee MK, Yvan-Charvet L, Masters SL, Murphy AJ. The modern interleukin-1 superfamily: Divergent roles in obesity. Semin Immunol. 2016 Oct 7. pii: S1044-5323(16)30100-2.
Disruption of Glut1 in Hematopoietic Stem Cells Prevents Myelopoiesis and Enhanced Glucose Flux in Atheromatous Plaques of ApoE-/- Mice
Sarrazy V, Viaud M, Westerterp M, Ivanov S, Giorgetti-Peraldi S, Guinamard R, Gautier EL, Thorp EB, De Vivo DC, Yvan-Charvet L
Circ. Res. 2016 Apr;118(7):1062-77 PMID : 26926469
Maintenance of Macrophage Redox Status by ChREBP Limits Inflammation and Apoptosis and Protects against Advanced Atherosclerotic Lesion Formation
Sarrazy V, Sore S, Viaud M, Rignol G, Westerterp M, Ceppo F, Tanti JF, Guinamard R, Gautier EL, Yvan-Charvet L
Cell Rep 2015 Oct;13(1):132-44 PMID : 26411684
Adipose modulation of ABCG1 uncovers an intimate link between sphingomyelin and triglyceride storage
Murphy AJ, Yvan-Charvet L
Diabetes 2015 Mar;64(3):689-92 PMID : 25713191
Cholesterol, inflammation and innate immunity
Tall AR, Yvan-Charvet L
Nat. Rev. Immunol. 2015 Feb;15(2):104-16 PMID : 25614320
Deficiency of ATP-binding cassette transporter B6 in megakaryocyte progenitors accelerates atherosclerosis in mice
Murphy AJ, Sarrazy V, Wang N, Bijl N, Abramowicz S, Westerterp M, Welch CB, Schuetz JD, Yvan-Charvet L
Arterioscler. Thromb. Vasc. Biol. 2014 Apr;34(4):751-8 PMID : 24504733
ATP-binding cassette transporters, atherosclerosis, and inflammation
Westerterp M, Bochem AE, Yvan-Charvet L, Murphy AJ, Wang N, Tall AR
Circ. Res. 2014 Jan;114(1):157-70 PMID : 24385509
Understanding macrophage diversity at the ontogenic and transcriptomic levels
Gautier EL, Yvan-Charvet L
Immunol. Rev. 2014 Nov;262(1):85-95 PMID : 25319329
Liver X receptor α-dependent iron handling in M2 macrophages: The missing link between cholesterol and intraplaque hemorrhage?
Hasty AH, Yvan-Charvet L
Circ. Res. 2013 Nov;113(11):1182-5 PMID : 24201110
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Murphy AJ, Bijl N, Yvan-Charvet L, Welch CB, Bhagwat N, Reheman A, Wang Y, Shaw JA, Levine RL, Ni H, Tall AR, Wang N
Nat. Med. 2013 May;19(5):586-94 PMID : 23584088
Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice
Westerterp M, Murphy AJ, Wang M, Pagler TA, Vengrenyuk Y, Kappus MS, Gorman DJ, Nagareddy PR, Zhu X, Abramowicz S, Parks JS, Welch C, Fisher EA, Wang N, Yvan-Charvet L, Tall AR
Circ. Res. 2013 May;112(11):1456-65 PMID : 23572498
HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders
Gautier EL, Westerterp M, Bhagwat N, Cremers S, Shih A, Abdel-Wahab O, Lütjohann D, Randolph GJ, Levine RL, Tall AR, Yvan-Charvet L
J. Exp. Med. 2013 Feb;210(2):339-53 PMID : 23319699
Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis
Ganda A, Magnusson M, Yvan-Charvet L, Hedblad B, Engström G, Ai D, Wang TJ, Gerszten RE, Melander O, Tall AR
Circulation 2013 Mar;127(9):988-96 PMID : 23378299
Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways
Westerterp M, Gourion-Arsiquaud S, Murphy AJ, Shih A, Cremers S, Levine RL, Tall AR, Yvan-Charvet L
Cell Stem Cell 2012 Aug;11(2):195-206 PMID : 22862945
Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis
Tall AR, Yvan-Charvet L, Westerterp M, Murphy AJ
Arterioscler. Thromb. Vasc. Biol. 2012 Nov;32(11):2547-52 PMID : 23077140
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport
Rosenson RS, Brewer HB, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L
Circulation 2012 Apr;125(15):1905-19 PMID : 22508840